Treatment of TB with Priftin (rifapentine)

To continue the research and development of the drug Priftin® (rifapentine) and to investigate its role in the treatment of active tuberculosis (TB) disease and latent TB infection.
Funding Partners:
  • Sanofi Foundation for North America
  • Sanofi-Aventis
Program Partners:
  • CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Program Location:
Texas, Colorado, California, Ohio, Washington DC, North Carolina, Tennessee, USA